Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
321.92
-9.07 (-2.74%)
Apr 28, 2026, 4:00 PM EDT - Market closed
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
8.97B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| Cytokinetics | 88.04M |
PRAX News
- 14 days ago - Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - GlobeNewsWire
- 22 days ago - Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial - Benzinga
- 22 days ago - Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewsWire
- 26 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
- 2 months ago - Praxis Precision Medicines Earnings Call Transcript: Q4 2025 - Transcripts